Life Sciences

  • May 21, 2026

    Vape Sellers Say Pa. E-Cig Law Usurps FDA Authority

    Vape companies are looking to stop a Pennsylvania law that would effectively ban most e-cigarettes, claiming in a federal lawsuit that the statute is unconstitutional, would destroy roughly $2 million of their inventory and targets products that federal regulators say helps smokers quit.

  • May 21, 2026

    Legislative Update: Cannabis And Psychedelics Bill Roundup

    Virginia's governor vetoed legislation to establish adult-use marijuana sales, keeping the state in cannabis legal limbo; Illinois lawmakers introduced legislation to rein in hemp products, aligning state policy with an upcoming shift in federal law; and Louisiana lawmakers sent a bill to the governor that would allow terminally ill patients to access medical marijuana in healthcare facilities. Here are the major moves in cannabis and psychedelics legislation from the past week.

  • May 21, 2026

    BigLaw Deals Scandal Puts Boston Back On White Collar Map

    A sweeping insider trading case involving information stolen from BigLaw firms shows a return to bread-and-butter white collar enforcement for Boston federal prosecutors and provides a morale lift in an office that has seen shifting priorities and staff turnover since the signature "Varsity Blues" takedown in 2019, veteran prosecutors told Law360.

  • May 21, 2026

    Immunity Bid Can't Stop Discovery In THC Abuse Registry Suit

    There's little chance that the Idaho state health director can ditch litigation by mothers challenging the automatic placement of women on the child abuse registry for prenatal THC use, a federal judge said after taking a "preliminary peek" at the state's pending motion to dismiss.

  • May 21, 2026

    Amgen Wants To Preserve Right To Seek Double Tax Relief

    Drugmaker Amgen wants to preserve its right to seek a refund for tax years 2010 through 2015 if the IRS "persists" in taking a position inconsistent with the agency's own arguments pertaining to those years in its audit of 2016 to 2018, the company told the U.S. Tax Court.

  • May 21, 2026

    Texas Comptroller Tells 5th Circ. To Toss E-Cig Ban Suit

    The acting comptroller for Texas is asking the Fifth Circuit to overturn an order allowing vape companies and a trade association to pursue a suit challenging a state law banning e-cigarette products that use liquids from China and other "adversaries," saying the comptroller is entitled to sovereign immunity.

  • May 21, 2026

    Fed. Circ. Backs Lupin Win In Generic Kidney Drug Case

    The Federal Circuit on Thursday affirmed a Delaware federal judge's ruling that Indian generic-drug maker Lupin's version of the kidney disease drug Jynarque does not infringe two patents held by Japanese rival Otsuka.

  • May 21, 2026

    AmeriHealth Unit, PBM Sued Over Prescription Claim Fees

    Two Philadelphia pharmacies have filed a proposed class action against AmeriHealth Caritas Health Plan and its in-house pharmacy benefits manager, PerformRx LLC, claiming the companies violate Pennsylvania law by not disclosing "transmission fees" at the time a claim is run through the pharmacies' computers, according to a complaint removed to federal court.

  • May 21, 2026

    Zantac Cases To Proceed During Appeal Of Recusal Denial

    The Philadelphia judge overseeing the city's Zantac cancer mass tort will not halt proceedings while Keller Postman LLC appeals his refusal to recuse himself from the litigation on the basis that his wife works at Blank Rome LLP, which represents a pharmaceutical company in one of the 550 cases.

  • May 20, 2026

    Prof. Hired By J&J In 1970s Found Asbestos In Talc, Jury Told

    A former Johnson & Johnson toxicologist could not find evidence his employer turned over a report to the U.S. Food and Drug Administration that "unmistakably" found asbestos in the company's talc, according to a video deposition shown Wednesday to a California jury considering bellwether claims over three women's deadly ovarian cancer.

  • May 20, 2026

    DOJ, Drugmakers Spar After Justices Snub 6 Negotiation Suits

    The U.S. Department of Justice is trying to have it both ways in drug pricing litigation, telling the U.S. Supreme Court not to intervene before additional circuits decide pending challenges and then using this week's nonintervention as ammunition against those challenges, drugmakers are arguing at appeals courts.

  • May 20, 2026

    Minnesota Jury Awards $10.2M In Talc Mesothelioma Trial

    A Minnesota state jury has delivered a $10.2 million verdict to a married couple in their suit against Vi-Jon LLC and the makers of other talc products like Johnson & Johnson and Gold Bond in which they alleged the 45-year-old husband's mesothelioma was caused by exposure to body powder products.

  • May 20, 2026

    2nd Circ. Skeptical Of Bid To Boost Drug Royalty Award

    A Second Circuit panel appeared unsympathetic during oral arguments on Wednesday to Acorda Therapeutics Inc.'s assertion that it should be awarded nearly $66 million beyond the $16.5 million it won in a multiple sclerosis drug dispute, with one judge remarking that the company is "kind of in the soup" because it chose arbitration.

  • May 20, 2026

    1st Circ. Allows Transfer Of RI Youth Care Info To Texas Court

    The First Circuit declined to halt a Texas federal court's order requiring a Rhode Island hospital to hand over records detailing its provision of gender-affirming care to minors, finding a Rhode Island agency failed to demonstrate that doing so would cause children in the state irreparable harm.

  • May 20, 2026

    Refusing Sandoz Parent Dismissal 'Clear Error,' Court Told

    Sandoz's Swiss parent company wants a Pennsylvania federal judge to rethink her decision forcing it to face generic drug price-fixing claims from major employers like General Motors, arguing the court "conflates" Novartis AG with Sandoz AG, which was spun off in 2023.

  • May 20, 2026

    Eli Lilly Loses Bid To Limit Ex-FDA Chief's Take In GLP-1 MDL

    A Pennsylvania federal judge said Eli Lilly & Co. and plaintiffs in multidistrict litigation accusing it of downplaying side effects of weight loss drugs were talking past each other in a dispute over expert testimony, denying Eli Lilly's bid to limit the opinions of the plaintiffs' expert to those disclosed in his report.

  • May 20, 2026

    Tiversa Escapes LabMD's Final Defamation Claims

    A defunct cancer screening lab cannot show that a cybersecurity firm CEO had "actual malice" when he made allegedly defamatory statements about a file of private health info being "exposed," "leaked" and "publicly available" nearly 20 years ago, a federal magistrate ruled in dismissing a long-running lawsuit Tuesday.

  • May 20, 2026

    Eli Lilly Paying Up To $202M In Genetic Medicine Deal

    Eli Lilly and Co. has agreed to acquire privately held Engage Biologics Inc., which is developing a delivery technology for genetic medicines, in a deal worth up to $202 million, Cooley LLP-advised Engage announced Wednesday.

  • May 20, 2026

    Intellia Drops Counterclaims In Gene-Editing Patent Case

    Intellia Therapeutics Inc. has agreed to drop a set of claims it asserted in a Delaware federal suit brought by BlueAllele, which accused it of infringing three gene-editing patents to bring in $100 million in a deal with Regeneron Pharmaceuticals.

  • May 20, 2026

    Squires Institutes 5 Patent Reviews, Rejects 7 Others

    U.S. Patent and Trademark Office Director John Squires on Tuesday granted five requests for review of patents under the America Invents Act while turning down seven other petitions.

  • May 20, 2026

    FTC 'Close' To Final PBM Insulin Price Deal With OptumRx

    Federal Trade Commission staffers have signaled that they're near a settlement with UnitedHealth Group Inc.'s OptumRx that would close out the agency's in-house case accusing pharmacy benefit managers of inflating insulin prices through rebate schemes.

  • May 19, 2026

    Quinn Emanuel Owes More Sanctions In Guardant Fight

    Quinn Emanuel and its team representing medical testing company Natera will shoulder further sanctions on top of the $3 million already imposed over the firm's misrepresentations concerning an expert witness in Guardant Health's false advertising case, a California federal judge ruled Tuesday.

  • May 19, 2026

    Monsanto To Pay Mich., RI Up To $302M Over PCB Pollution

    Monsanto has reached multimillion-dollar deals with Michigan and Rhode Island to end claims that the company contaminated waterways and natural resources with polychlorinated biphenyls, agreeing to pay the states as much as $240 million and $62 million, respectively, with most of that money contingent on how the company recovers from separate lawsuits.

  • May 19, 2026

    Toxicologist Denies J&J Wanted To 'Control' Talc Study

    A former Johnson & Johnson toxicologist denied the company controlled a 1970s study of talc miners by insisting "you do not control" people like the professor behind the study, in a video deposition shown Tuesday to a California jury considering bellwether claims the company's talc products caused deadly ovarian cancer in three women.

  • May 19, 2026

    Calif. Urges 9th Circ. To Revive Pay-For-Delay Restrictions

    California urged a Ninth Circuit panel Tuesday to find a Golden State law that bans drugmakers from cutting deals out of state that pay to delay generics competition doesn't violate the U.S. Constitution, arguing that ruling otherwise could jeopardize many longstanding state laws that regulate out-of-state conduct.

Expert Analysis

  • How 11th Circ.'s Qui Tam Review Could Affect FCA Litigation

    Author Photo

    On Dec. 12, the Eleventh Circuit will hear arguments in U.S. ex rel. Zafirov v. Florida Medical Associates, setting the stage for a decision that could drastically reduce enforcement under the False Claims Act, and presenting an opportunity to seek U.S. Supreme Court review of the act's whistleblower provisions, say attorneys at Epstein Becker.

  • Series

    The Biz Court Digest: Welcome To Miami

    Author Photo

    After nearly 20 years in operation, the Miami Complex Business Litigation Division is a pioneer upon which other jurisdictions in the state have been modeled, adopting many innovations to keep its cases running more efficiently and staffing experienced judges who are accustomed to hearing business disputes, say attorneys at King & Spalding.

  • Identifying And Resolving Conflicts Among Class Members

    Author Photo

    As the Fifth Circuit's recent decision in Nova Scotia Health Employees' Pension Plan v. McDermott International illustrates, intraclass conflicts can determine the fate of a class action — and such conflicts can be surprisingly difficult to identify, says Andrew Faisman, a clerk at the U.S. District Court for the Southern District of New York.

  • Adapting To A Plaintiff-Side Mindset For Patent Monetization

    Author Photo

    A recent decrease in risk for patent owners at the U.S. Patent and Trademark Office, combined with increased corporate interest in monetizing patent assets, creates an attractive case for evaluating patents from a plaintiff-side mindset, but in-house counsel transitioning from a defense-side mindset to a plaintiff-side mindset should study certain considerations, says Kate Tellez at Steptoe.

  • AI Evidence Rule Tweaks Encourage Judicial Guardrails

    Author Photo

    Recent additions to a committee note on proposed Rule of Evidence 707 — governing evidence generated by artificial intelligence — seek to mitigate potential dangers that may arise once machine outputs are introduced at trial, encouraging judges to perform critical gatekeeping functions, say attorneys at Lankler Siffert & Wohl.

  • Series

    The Law Firm Merger Diaries: Getting The Message Across

    Author Photo

    Communications and brand strategy during a law firm merger represent a crucial thread that runs through every stage of a combination and should include clear messaging, leverage modern marketing tools and embrace the chance to evolve, says Ashley Horne at Womble Bond.

  • Opinion

    Horizontal Stare Decisis Should Not Be Casually Discarded

    Author Photo

    Eliminating the so-called law of the circuit doctrine — as recently proposed by a Fifth Circuit judge, echoing Justice Neil Gorsuch’s concurrence in Loper Bright — would undermine public confidence in the judiciary’s independence and create costly uncertainty for litigants, says Lawrence Bluestone at Genova Burns.

  • 10 Commandments For Agentic AI Tools In The Legal Industry

    Author Photo

    Though agentic artificial intelligence has demonstrated significant promise for optimizing legal work, it presents numerous risks, so specific ethical obligations should be built into the knowledge base of every agentic AI tool used in the legal industry, says Steven Cordero at Akerman LLP.

  • Fed. Circ. In Oct.: Spotlight On Wording Beyond Patent Claims

    Author Photo

    The Federal Circuit's recent decision in Barrette Outdoor Living v. Fortress Iron provides useful guidance on how patent prosecutors should avoid language that triggers specification disclaimer and prosecution disclaimer, doctrines that may be used to narrow the scope of patent infringement claims, say attorneys at Knobbe Martens.

  • New Drug Ad Regs Could Lead To A Less Informed Public

    Author Photo

    A federal push to mandate full safety warnings in pharmaceutical advertising could make drug ads less appealing for companies to air, which in turn could negatively affect consumers' health decisions by removing an accessible information source, say Punam Keller at Dartmouth College and Ceren Canal Aruoba at Berkeley Research Group.

  • Series

    Preaching Makes Me A Better Lawyer

    Author Photo

    Becoming a Gospel preacher has enhanced my success as a trial lawyer by teaching me the importance of credibility, relatability, persuasiveness and thorough preparation for my congregants, the same skills needed with judges and juries in the courtroom, says Reginald Harris at Stinson.

  • A Look At Middlemen Fees In 340B Drug Discount Program

    Author Photo

    A U.S. Senate committee's recent hearing on the Section 340B drug discount program, along with statistical analysis of payment amounts, contribute to a growing consensus that middlemen fees are too high, say William Sarraille at the University of Maryland, and Shanyue Zeng and Rory Martin at IQVIA.

  • How Large Patent Damages Awards Actually Play Out

    Author Photo

    Most large verdicts in patent infringement cases are often overturned or reduced on appeal, implying that the Federal Circuit is serving its intended purpose of correcting outlier outcomes, and that the figures that catch headlines and dominate policy debates may misrepresent economic realities, says Bowman Heiden at Berkeley School of Law.

  • Series

    Law School's Missed Lessons: Practicing Client-Led Litigation

    Author Photo

    New litigators can better help their corporate clients achieve their overall objectives when they move beyond simply fighting for legal victory to a client-led approach that resolves the legal dispute while balancing the company's competing out-of-court priorities, says Chelsea Ireland at Cohen Ziffer.

  • Navigating 2025's Post-Grant Proceeding Shakeups

    Author Photo

    Extensive changes to the U.S. Patent Trial and Appeal Board's post-grant proceedings this year, including the new settled expectations factor and revitalization of Fintiv factors, require petitioners and patent owners alike to be mindful when selecting patents to assert and challenge, say attorneys at Quinn Emanuel.

Want to publish in Law360?


Submit an idea

Have a news tip?


Contact us here
Can't find the article you're looking for? Click here to search the Life Sciences archive.